DE69807222T2 - (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen - Google Patents

(imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen

Info

Publication number
DE69807222T2
DE69807222T2 DE69807222T DE69807222T DE69807222T2 DE 69807222 T2 DE69807222 T2 DE 69807222T2 DE 69807222 T DE69807222 T DE 69807222T DE 69807222 T DE69807222 T DE 69807222T DE 69807222 T2 DE69807222 T2 DE 69807222T2
Authority
DE
Germany
Prior art keywords
sub
sup
alkyl
alkyloxy
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69807222T
Other languages
English (en)
Other versions
DE69807222D1 (de
Inventor
William End
J Zelesko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of DE69807222D1 publication Critical patent/DE69807222D1/de
Publication of DE69807222T2 publication Critical patent/DE69807222T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE69807222T 1997-06-02 1998-05-25 (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen Expired - Lifetime DE69807222T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4737697P 1997-06-02 1997-06-02
PCT/EP1998/003182 WO1998055124A1 (en) 1997-06-02 1998-05-25 (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation

Publications (2)

Publication Number Publication Date
DE69807222D1 DE69807222D1 (de) 2002-09-19
DE69807222T2 true DE69807222T2 (de) 2003-04-17

Family

ID=21948611

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69807222T Expired - Lifetime DE69807222T2 (de) 1997-06-02 1998-05-25 (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen

Country Status (22)

Country Link
US (4) US6365600B1 (de)
EP (1) EP0988038B1 (de)
JP (1) JP4209472B2 (de)
KR (1) KR100517832B1 (de)
CN (2) CN100525766C (de)
AT (1) ATE222104T1 (de)
AU (1) AU740603B2 (de)
BR (1) BR9810423A (de)
CA (1) CA2290992C (de)
DE (1) DE69807222T2 (de)
DK (1) DK0988038T3 (de)
ES (1) ES2182327T3 (de)
HK (2) HK1025046A1 (de)
ID (1) ID24675A (de)
IL (1) IL133212A (de)
NO (1) NO318834B1 (de)
NZ (1) NZ501401A (de)
PT (1) PT988038E (de)
RU (1) RU2209066C2 (de)
TR (1) TR199902923T2 (de)
WO (1) WO1998055124A1 (de)
ZA (1) ZA984700B (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2290992C (en) 1997-06-02 2008-02-12 Janssen Pharmaceutica N.V. (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
US20030040790A1 (en) * 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
US20020099438A1 (en) * 1998-04-15 2002-07-25 Furst Joseph G. Irradiated stent coating
KR100674122B1 (ko) * 1998-07-06 2007-01-26 얀센 파마슈티카 엔.브이. 관절증 치료용 파네실 단백질 트랜스퍼라제 억제제
US7967855B2 (en) 1998-07-27 2011-06-28 Icon Interventional Systems, Inc. Coated medical device
US8070796B2 (en) 1998-07-27 2011-12-06 Icon Interventional Systems, Inc. Thrombosis inhibiting graft
JP3494409B2 (ja) * 1998-08-27 2004-02-09 ファイザー・プロダクツ・インク 抗がん剤として有用なアルキニル置換キノリン−２−オン誘導体
PT1140935E (pt) * 1998-12-23 2003-10-31 Janssen Pharmaceutica Nv Derivados da quinolina 1,2-ciclizada
IL144307A0 (en) 1999-02-11 2002-05-23 Pfizer Prod Inc Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
TR200400342T4 (tr) 1999-11-30 2004-03-22 Pfizer Products Inc. Farnezil protein transferazı önlemek için kinolin türevleri.
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
ATE386736T1 (de) 2000-09-11 2008-03-15 Novartis Vaccines & Diagnostic Verfahren zur herstellung von benzimidazol-2-yl - chinolinonderivaten
FR2813791B1 (fr) * 2000-09-14 2004-03-12 Lafon Labor Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale
EP1322635B1 (de) 2000-09-25 2006-03-22 Janssen Pharmaceutica N.V. Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
AU2002220559A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
WO2002024683A1 (en) * 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives
JP4974439B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
DE60139080D1 (de) 2000-11-21 2009-08-06 Janssen Pharmaceutica Nv Farnesyltransferase hemmende benzoheterocyclische derivate
ATE319704T1 (de) 2000-12-27 2006-03-15 Janssen Pharmaceutica Nv Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
WO2003000266A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
EP1458720B1 (de) 2001-12-19 2009-03-18 Janssen Pharmaceutica N.V. Durch c-verbundene imidazole substituierte 1,8-annellierten chinolon-derivate als farnesyl transferase inhibitoren
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
AU2003223970B2 (en) 2002-03-22 2008-03-06 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
ES2271574T3 (es) 2002-04-15 2007-04-16 Janssen Pharmaceutica N.V. Derivados triciclicos de quinazolina inhibidores de la farnesiltransferasa, sustituidos con imidazoles o triazoles enlazados al carbono.
US8016881B2 (en) 2002-07-31 2011-09-13 Icon Interventional Systems, Inc. Sutures and surgical staples for anastamoses, wound closures, and surgical closures
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US6638301B1 (en) * 2002-10-02 2003-10-28 Scimed Life Systems, Inc. Medical device with radiopacity
EP1565187A4 (de) 2002-11-13 2010-02-17 Novartis Vaccines & Diagnostic Verfahren zur behandlung von krebs undverwandte verfahren
US20050154451A1 (en) * 2003-12-18 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
NZ547277A (en) * 2004-01-23 2009-08-28 Janssen Pharmaceutica Nv Substituted quinolines and their use as mycobacterial inhibitors
US7211108B2 (en) * 2004-01-23 2007-05-01 Icon Medical Corp. Vascular grafts with amphiphilic block copolymer coatings
JP5019884B2 (ja) 2004-02-20 2012-09-05 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 炎症プロセスおよび転移プロセスの調節
BRPI0508703B8 (pt) * 2004-03-15 2021-05-25 Anormed Inc processo para a síntese de um antagonista de cxcr4
EP1744751A4 (de) * 2004-03-18 2010-03-10 Brigham & Womens Hospital Verfahren zur behandlung von synucleinopathien
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
EP1732549A4 (de) * 2004-03-18 2009-11-11 Brigham & Womens Hospital Verfahren zur behandlung von synucleinopathien
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US7063720B2 (en) * 2004-09-14 2006-06-20 The Wallace Enterprises, Inc. Covered stent with controlled therapeutic agent diffusion
US20060083770A1 (en) * 2004-10-15 2006-04-20 Specialty Coating Systems, Inc. Medical devices and methods of preparation and use
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US20060264914A1 (en) * 2005-03-03 2006-11-23 Icon Medical Corp. Metal alloys for medical devices
US7540995B2 (en) 2005-03-03 2009-06-02 Icon Medical Corp. Process for forming an improved metal alloy stent
US8323333B2 (en) * 2005-03-03 2012-12-04 Icon Medical Corp. Fragile structure protective coating
WO2006110197A2 (en) 2005-03-03 2006-10-19 Icon Medical Corp. Polymer biodegradable medical device
US20060201601A1 (en) * 2005-03-03 2006-09-14 Icon Interventional Systems, Inc. Flexible markers
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
US20060200048A1 (en) * 2005-03-03 2006-09-07 Icon Medical Corp. Removable sheath for device protection
KR101368519B1 (ko) 2005-05-23 2014-02-27 노파르티스 아게 결정형 및 기타 형태의 4-아미노-5-플루오로-3-［6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일］-1ｈ-퀴놀린-2-온 락트산염
CA2617213C (en) 2005-07-29 2014-01-28 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
CA2634598A1 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
US20070148390A1 (en) * 2005-12-27 2007-06-28 Specialty Coating Systems, Inc. Fluorinated coatings
ATE547394T1 (de) * 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
NZ579355A (en) 2007-02-01 2012-03-30 Resverlogix Corp 2-(Aryl)-4-oxo-quinazoline derivatives
WO2008147788A1 (en) * 2007-05-23 2008-12-04 Allergan, Inc. Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
EP2346837B8 (de) 2008-06-26 2015-04-15 Resverlogix Corporation Verfahren zur herstellung von chinazolinonderivaten
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
CA2743717A1 (en) * 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
EP2660238B1 (de) 2009-01-08 2015-05-06 Resverlogix Corporation Verbindungen zur Vorbeugung und Behandlung von kardiovaskulären Erkrankungen
KR101803259B1 (ko) 2009-03-18 2017-11-30 리스버로직스 코퍼레이션 신규한 소염제
BRPI1014956B8 (pt) 2009-04-22 2021-05-25 Resverlogix Corp agentes anti-inflamatórios
US8398916B2 (en) 2010-03-04 2013-03-19 Icon Medical Corp. Method for forming a tubular medical device
LT2773354T (lt) 2011-11-01 2019-08-12 Resverlogix Corp. Geriamosios greitai atsipalaiduojančios pakeistų chinozolinų vaisto formos
CN104093709B (zh) * 2012-02-13 2017-09-22 霍夫曼-拉罗奇有限公司 作为醛固酮合酶抑制剂的咪唑基酮衍生物
BR112015008515A2 (pt) * 2012-10-16 2017-07-04 Janssen Pharmaceutica Nv moduladores de ror t de quinolinila ligada à heteroarila
CN105073729A (zh) 2012-10-16 2015-11-18 詹森药业有限公司 RORγt的苯基连接的喹啉基调节剂
AR093017A1 (es) 2012-10-16 2015-05-13 Janssen Pharmaceutica Nv MODULARES DE RORgT DE QUINOLINILO UNIDOS POR METILENO
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
MX2015007921A (es) 2012-12-21 2016-03-03 Zenith Epigenetics Corp Compuestos heterociclicos novedosos como inhibidores de bromodominio.
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
BR112016008215A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2015199816A1 (en) 2014-06-24 2015-12-30 Icon Medical Corp. Improved metal alloys for medical devices
WO2016100782A1 (en) * 2014-12-18 2016-06-23 University Of South Carolina Suppression of neointimal formation following vascular surgery using cdk8 inhibitors
EP3268007B1 (de) 2015-03-13 2022-11-09 Resverlogix Corp. Zusammensetzungen und therapeutische verfahren zur behandlung von komplementassoziierten erkrankungen
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
PT3277842T (pt) 2015-08-17 2019-09-05 Kura Oncology Inc Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
US10953003B2 (en) 2015-12-14 2021-03-23 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP7055380B2 (ja) 2015-12-22 2022-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 免疫不全疾患を処置するための方法
US11766506B2 (en) 2016-03-04 2023-09-26 Mirus Llc Stent device for spinal fusion
EP3440112A4 (de) 2016-04-08 2019-10-09 X4 Pharmaceuticals, Inc. Verfahren zur behandlung von krebs
CA3027498A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11332470B2 (en) 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
EA201991091A1 (ru) 2016-11-03 2019-11-29 Способы лечения пациентов со злокачественными новообразованиями с применением ингибиторов фарнезилтрансферазы
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN110204487B (zh) * 2019-06-21 2021-09-28 江南大学 一种喹啉衍生物的合成方法
CN113072490B (zh) * 2021-03-26 2022-08-16 中国海洋大学 一种替吡法尼喹啉酮中间体的高效合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE456347B (sv) 1982-02-09 1988-09-26 Ird Biomaterial Ab Ytmodifierat fast substrat samt forfarande for framstellning derav
US5049403A (en) 1989-10-12 1991-09-17 Horsk Hydro A.S. Process for the preparation of surface modified solid substrates
US5213898A (en) 1989-10-12 1993-05-25 Norsk Hydro A.S. Process for the preparation of surface modified solid substrates
US5356433A (en) 1991-08-13 1994-10-18 Cordis Corporation Biocompatible metal surfaces
JPH07112930A (ja) * 1993-10-14 1995-05-02 Kyowa Hakko Kogyo Co Ltd 血管平滑筋細胞増殖抑制剤
DE69623455T2 (de) 1995-04-19 2003-01-16 Schneider Usa Inc Beschichteter dilatator zur abgabe eines arzneistoffs
US5607475A (en) 1995-08-22 1997-03-04 Medtronic, Inc. Biocompatible medical article and method
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
PT1162201E (pt) * 1995-12-08 2006-08-31 Janssen Pharmaceutica Nv Derivados de ( imidazol-5-il ) metil-2-quinolinona como inibidores da proteina farnesil transferase
CA2290992C (en) 1997-06-02 2008-02-12 Janssen Pharmaceutica N.V. (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation

Also Published As

Publication number Publication date
US7253183B2 (en) 2007-08-07
AU740603B2 (en) 2001-11-08
ZA984700B (en) 1999-12-01
IL133212A0 (en) 2001-03-19
NO995883L (no) 2000-02-02
CA2290992A1 (en) 1998-12-10
ES2182327T3 (es) 2003-03-01
PT988038E (pt) 2002-12-31
CA2290992C (en) 2008-02-12
TR199902923T2 (xx) 2000-11-21
US20040198771A1 (en) 2004-10-07
ID24675A (id) 2000-07-27
WO1998055124A1 (en) 1998-12-10
HK1088820A1 (en) 2006-11-17
BR9810423A (pt) 2000-10-03
KR100517832B1 (ko) 2005-09-30
EP0988038B1 (de) 2002-08-14
US6734194B2 (en) 2004-05-11
IL133212A (en) 2005-12-18
NO995883D0 (no) 1999-12-01
US20030229118A1 (en) 2003-12-11
AU8020798A (en) 1998-12-21
ATE222104T1 (de) 2002-08-15
HK1025046A1 (en) 2000-11-03
US6365600B1 (en) 2002-04-02
CN1231215C (zh) 2005-12-14
KR20010012782A (ko) 2001-02-26
CN100525766C (zh) 2009-08-12
JP4209472B2 (ja) 2009-01-14
DE69807222D1 (de) 2002-09-19
CN1762355A (zh) 2006-04-26
NZ501401A (en) 2002-03-28
DK0988038T3 (da) 2002-12-02
RU2209066C2 (ru) 2003-07-27
CN1265585A (zh) 2000-09-06
JP2002503235A (ja) 2002-01-29
US20020091138A1 (en) 2002-07-11
US6743805B2 (en) 2004-06-01
NO318834B1 (no) 2005-05-09
EP0988038A1 (de) 2000-03-29

Similar Documents

Publication Publication Date Title
DE69807222T2 (de) (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen
EP1162201A3 (de) (Imidazol-5-yl)Methyl-2-Chinolinonderivate als Farnesyl Protein transferase Inhibitoren
Neznanov et al. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib
RU2000100032A (ru) Производные (имидазол-5-ил)метил-2-хинолинона в качестве ингибиторов пролиферации клеток гладкой мышцы
PL356252A1 (en) Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
Pollack et al. Lack of prostate cancer radiosensitization by androgen deprivation
NO931766D0 (no) Topiske preparater for transdermal avlevering av forloeperlegemiddelderivater av morfin
BR9808843A (pt) Derivados de quinolinona 1,8-anelados inibidores da farnesil transferase substituìdos com imidazóis ligados em n ou em c
EE03523B1 (et) Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine
DE602004006165D1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
Byfield et al. Mice, men, mustards and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agents
CO5200778A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
NZ308391A (en) Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers
IS2387B (is) Æxliseyðandi efni
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с
CO5190664A1 (es) Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
BR9915390A (pt) Tratamento de tumores através de administração de compostos que liberam harmÈnio de crescimento e seus antagonistas
BR9709556A (pt) Dihidrobenzopirano e compostos a ele relacionados úteis como agentes antiflamatórios
Hattori et al. Synergistic effect of indomethacin with adriamycin and cisplatin on tumor growth
BR0012502A (pt) Inibidores da expressão do gene para interleucina 5
RU94044323A (ru) Средство ингибирования навязчиво-компульсивных состояний и расстройств потребления
BR9610077A (pt) Utilização de um composto e associação
PL1680076T3 (pl) Farmaceutyczne i kosmetyczne kompozycje do leczenia paznokci

Legal Events

Date Code Title Description
8364 No opposition during term of opposition